Risk-Based Oversight Redefined: How E6R3 is Reshaping Vendor Governance
At the SCOPE Europe 2025 conference, industry experts underscored how ICH E6(R3) is transforming the way sponsors approach vendor...
Imaging as Infrastructure: Why Sponsors Must Rethink Oversight in Modern Trials
At DPHARM, we spoke with Paul McCracken, founder and principal of RadiaNova Consulting, about the overlooked pitfalls in clinical...
“Minutes, Not Days”: Site-Centric AI and Clinical Trial Experience
The coordinator stared at a 400-page EHR export, convinced the week was lost—until an AI pre-screen flagged 23 likely-eligible...
How Small Biotechs Navigate Clinical Trial Vendor Oversight
At SCOPE Europe 2025, a panel on vendor identification, selection, and management highlighted a pragmatic blueprint for small biopharma:...
The Human Cost of Fragmented Technology: A Conversation with Veeva’s Bree Burks
At the Veeva R&D and Quality Summit in Boston, we spoke with Bree Burks, Vice President of Strategy at...
Northwell Christina Brennan on Future of Site-Sponsor Partnerships
At the Veeva R&D and Quality Summit in Boston, we interviewed Dr. Christina Brennan, Senior Vice President of Clinical...
Redefining Imaging Workflows in Clinical Trials
At the Veeva R&D and Quality Summit in Boston, Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve...
What Research Sites Say They Need from Sponsors
At Veeva’s 2025 R&D & Quality Summit, site leaders described how brittle identity systems, sprawling vendor networks, and poorly...
Pharma’s Next Opportunity: AI and Standardization
At Veeva R&D and Quality Summit in Boston, the pain points of managing complex processes and entering data manually...
Sanofi Anticipates a 30% Cost Reduction With Veeva Training System
At the 2025 Veeva R&D and Quality Summit, Sanofi unveiled a transformative approach to study training within clinical operations,...